Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of placebo and valdecoxib. Placebo is an inert substance with no pharmacological activity, used as a control in clinical trials. Valdecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that acts as a selective cyclooxygenase-2 (COX-2) inhibitor, providing anti-inflammatory, analgesic, and antipyretic effects. It was primarily indicated for the treatment of osteoarthritis, rheumatoid arthritis, and primary dysmenorrhea but was withdrawn from major markets due to safety concerns related to cardiovascular events and serious skin reactions[1][2][4][5]. The combination "placebo + valdecoxib" would be used only in the context of clinical research or trials comparing active drug versus inactive control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placebo + valdecoxib.